VAP prevention: non-pharmacological strategies

M. Valencia, G. Li Bassi, A. Torres

Source: Eur Respir Monogr 2011; 53: 83-97
Disease area: Respiratory critical care, Respiratory infections

Congress or journal article abstractFull text journal article

Abstract

Summary

Ventilator-associated pneumonia (VAP) is one of the most common infections in the intensive care unit (ICU) and is associated with high morbidity, mortality and costs. As a result, prevention of VAP is highly relevant in critical care settings. Pulmonary aspiration of colonised oropharyngeal secretions across the tracheal tube cuff is the main pathogenic mechanism for development of VAP. Recently, several strategies have been applied to improve the design of tracheal tubes and reduce the likelihood of aspiration of pathogen-laden secretions across the cuff. The use of endotracheal tubes that allow aspiration of subglottic secretions have demonstrated a decrease in the rate of VAP. In critically ill patients, following tracheal intubation oral flora frequently shifts into a predominance of aerobic Gram-negative pathogens. Extensive efforts have been devoted to reducing the risks of oropharyngeal colonisation with pathogens, including selective digestive decontamination (SDD). Although SDD is a controversial measure, it reduces the incidence of VAP and respiratory infections. The long-term effects of SDD on the emergence of bacterial resistance and risk of superinfections are still controversial.



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Valencia, G. Li Bassi, A. Torres. VAP prevention: non-pharmacological strategies. Eur Respir Monogr 2011; 53: 83-97

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Relationship between tracheotomy and ventilator-associated pneumonia: a case control study
Source: Eur Respir J 2007; 30: 314-320
Year: 2007



VAP prevention: pharmacological strategies
Source: Eur Respir Mon 2011; 53: 74-82
Year: 2011


Efficacy of a ventilator bundle for the prevention of the ventilator-associated pneumonia
Source: Annual Congress 2011 - Mechanical ventilation and lung injury: new advances
Year: 2011

Empyema treatment: about drains, fibrinolytics and when to call the surgeon
Source: Annual Congress 2007 - PG16 - Management of pleural problems in your practice today
Year: 2007



The association of ventilator-associated pneumonia with the frequent exchange of endotracheal tube
Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Year: 2016


Prevention of VAP: role of the artificial airway, body position and setting the ventilator
Source: Eur Respir Mon 2012; 55: 153-168
Year: 2012


Invasive interventions: mini-trach and -tracheostomy – who is the adequate patient?
Source: Annual Congress 2005 - Management of airway hypersecretions
Year: 2005

Antibiotic use
Source: Annual Congress 2005 - Protocols in the critically ill patient
Year: 2005

Implications of identifying the pathogen in ventilator-associated pneumonia (VAP)
Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU
Year: 2013


Effect of de-escalation antibiotic therapy on hospital-acquired, ventilator associated, and healthcare-associated pneumonia: A systematic review and meta-analysis
Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Year: 2016

Non-antibiotic treatment for severe pneumonia?
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005

Automatic control of the tracheal cuff pressure does not prevent ventilator-associated pneumonia (VAP)
Source: Annual Congress 2005 - Diagnosis and prognosis of ventilator associated pneumonia: the clinical track
Year: 2005


Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011



Effectiveness and safety of a protocolized mechanical ventilation and weaning strategy of COPD patients by respiratory therapists
Source: Annual Congress 2013 –Mechanical ventilation and weaning
Year: 2013

Novel jet nebulizer/holding chamber for drug delivery to the deep lung
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016

Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
Source: Eur Respir J 2006; 27: 158-164
Year: 2006



Who should treat these patients: intensivists or pneumologists?
Source: Annual Congress 2006 - PG6 - Respiratory failure: noninvasive ventilation and techniques of diagnosis for hypoxic respiratory failure
Year: 2006



Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines
Source: Eur Respir J 2003 Dec 01;22(6):876-882
Year: 2003